News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Broad U.S. equity indices reached fresh highs on strong Q2 earnings momentum.
  • An AI-driven stock selection strategy has posted cumulative returns near +200% since November 2023, outperforming the S&P 500.
  • U.S. Treasury began disbursing roughly $100 billion in tariff refunds certified after the Supreme Court ruling.
  • Motorola raised full-year guidance, News Corp topped revenue estimates, and Trekor reported $125 million adjusted EBITDA.
  • Axon reported compressed gross margins and saw shares fall more than 6% in aftermarket trading.
  • Beyond Meat reported revenue declines and negative adjusted EBITDA, signaling ongoing operational weakness.
  • Canadian Prime Minister Mark Carney quipped about a teleprompter failure and jabbed at Trump during a Toronto housing-policy press conference.

Latest Articles

Inspira Technologies Secures Fully Paid $390,000  Purchase Order and Recurring Revenue Stream from Premier APAC University

Inspira Technologies Secures Fully Paid $390,000 Purchase Order and Recurring Revenue Stream from Premier APAC University

Inspira Technologies announced receipt of a fully paid $390,000 purchase order for its additive manufacturing electronics (AME) system from a premier Asia-Pacific technological research university specializing in quantum computing. The purchase establishes a recurring revenue stream through consumables and service fees. Inspira's AME technology sup…

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Silexion Therapeutics Announces Successful Submission of Phase 2/3 Clinical Trial Application to Germany’s BfArM for SIL204 in KRAS-Driven Locally Advanced Pancreatic Cancer

Silexion Therapeutics has successfully submitted a Clinical Trial Application to Germany's BfArM for its Phase 2/3 study of SIL204, an innovative siRNA therapy targeting KRAS-driven locally advanced pancreatic cancer. This regulatory milestone follows Israeli approval and marks the company's expansion into the European clinical development landscap…

GM shares dip despite sizable first-quarter earnings beat

GM shares dip despite sizable first-quarter earnings beat

General Motors reported first-quarter adjusted EBIT of $4.3 billion, a 9.7% margin that exceeded analyst estimates by a wide margin, and raised its full-year adjusted EBIT guidance. The company cited operational strength in North America, foreign exchange benefits, and an approximately $500 million tariff-related adjustment. Despite the beat and a …

Shimmick Corporation Appoints Sarah Tacker as Executive Vice President and Chief Operating Officer

Shimmick Corporation Appoints Sarah Tacker as Executive Vice President and Chief Operating Officer

Shimmick Corporation (NASDAQ: SHIM), a leading infrastructure solutions company, announced the appointment of Sarah Tacker as Executive Vice President and Chief Operating Officer. With 27 years of construction industry experience, Ms. Tacker will lead the company’s operational functions to improve execution and support scaling efforts. This strateg…

Brazil’s Mid-April Prices Rise Less Than Forecast, Keeping Rate Cut Odds High

Brazil’s Mid-April Prices Rise Less Than Forecast, Keeping Rate Cut Odds High

Brazil's mid-April consumer-price gauge showed an annual rise of 4.37%, below economists' forecasts, and a monthly increase of 0.89%. The softer-than-expected outcome reinforces market expectations that the central bank will trim its benchmark interest rate by 25 basis points to 14.50% at its upcoming meeting as policymakers weigh inflation pressur…

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Quoin Pharmaceuticals has announced plans to initiate several investigator-led clinical studies for its QRX009 topical rapamycin lotion targeting rare skin diseases including Pachyonychia Congenita, Gorlin Syndrome, and Tuberous Sclerosis Complex. The company expects to submit an Investigational New Drug Application to the FDA for an additional ind…

GSI Technology Awarded U.S. Army xTech SBIR Contract to Develop Ruggedized Edge AI Platform for Tactical Defense Applications

GSI Technology Awarded U.S. Army xTech SBIR Contract to Develop Ruggedized Edge AI Platform for Tactical Defense Applications

GSI Technology, a pioneer in Associative Processing Unit (APU) technology, announced it has been awarded a Phase-II U.S. Army xTech SBIR contract valued at approximately $2 million to develop a ruggedized edge AI platform using its Gemini-II APU. The contract supports the design, fabrication, and validation of a low-power, high-performance AI proce…

Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology

Nuwellis Announces Receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for Innovative Dual Lumen Midline Catheter Technology

Nuwellis, Inc. announced the receipt of a Notice of Allowance from the USPTO for its innovative dual lumen midline catheter technology designed to optimize ultrafiltration therapy. The patented catheter features advanced design elements that improve blood flow and customize catheter length for diverse patient anatomies, aiming to enhance patient ou…

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

PolyPid Ltd., a biopharmaceutical company listed on Nasdaq, announced upcoming presentation of detailed analysis from its Phase 3 SHIELD II trial at the 2026 Surgical Infection Society Annual Meeting. The data demonstrate a statistically significant reduction in both the incidence and severity of surgical site infections (SSI) following colorectal …